Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 15;13(8):1428.
doi: 10.3390/diagnostics13081428.

Update on the Role of FeNO in Asthma Management

Neveda Murugesan  1 , Damini Saxena  1 , Arundhati Dileep  2 , Muhammad Adrish  1 , Nicola A Hanania  1
Affiliations
Review

Update on the Role of FeNO in Asthma Management

Neveda Murugesan et al. Diagnostics (Basel). .

Abstract

Asthma is a heterogenous disorder characterized by presence of different phenotypes and endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective, point of care biomarker that is used to detect type 2 airway inflammation. Guidelines have proposed to measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation. FeNO has lower sensitivity, suggesting that it may not be a good biomarker to rule out asthma. FeNO may also be used to predict response to inhaled corticosteroids, predict adherence and deciding on biologic therapy. Higher levels of FeNO have been associated with lower lung function and increased risk for future asthma exacerbations and its predictive value increases when combined with other standard measurements of asthma assessment.

Keywords: FeNO; asthma; fractional excretion of nitric oxide; outcomes.

PubMed Disclaimer

Conflict of interest statement

N.M., D.S., A.D. and M.A. has no financial disclosures. N.A.H. received honoraria for serving as advisor or consultant for GSK, AstraZeneca, Sanofi, Regeneron, Amgen, Genentech, Novartis and Teva. His institution received research grant support of his behalf from GSK, Genentech, Sanofi, Teva, Novartis, and Astra Zeneca.

Figures

Figure 1
Figure 1
Diagnostic, prognostic, predictive value, and common confounders of FeNO use in asthma.
See this image and copyright information in PMC

References

    1. Soriano J.B., Alemu Abajobir A., Hassen Abate K., GBD 2015 Chronic Respiratory Disease Collaborators Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017;5:691–706. doi: 10.1016/S2213-2600(17)30293-X. - DOI - PMC - PubMed
    1. GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. - DOI - PMC - PubMed
    1. Tilemann L., Gindner L., Meyer F.J., Laux G., Szecsenyi J., Schneider A. Diagnostic value of peak flow variability in patients with suspected diagnosis of bronchial asthma in general practice. Dtsch. Med. Wochenschr. 2009;134:2053–2058. doi: 10.1055/s-0029-1237554. - DOI - PubMed
    1. Menzies-Gow A., Mansur A.H., Brightling C.E. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur. Respir. J. 2020;55:1901633. doi: 10.1183/13993003.01633-2019. - DOI - PubMed
    1. Wagener A.H., De Nijs S.B., Lutter R., Sousa A.R., Weersink E.J.M., Bel E.H., Sterk P.J. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120. doi: 10.1136/thoraxjnl-2014-205634. - DOI - PubMed

LinkOut - more resources